Introduction

Rheumatoid arthritis (RA) is one of the common inflammatory joint diseases. This autoimmune disease can be caused by a range of genetic and environmental factors. It affects people at any age stage but peaks between the ages of 30-50. The injury caused by this disease leads to the destruction of joints and impedes movement [1]. Inflammatory cells infiltrate into the synovial membrane in the RA joint, where the endothelial cells of the synovium swell with the formation of many new blood vessels. The inflamed synovium is called Pannus, and its formation leads to erosion of cartilage and bone, laxity and destruction of ligaments and tendons [2].

It has been observed that some physiological and immunological markers (hormones, interleukins, growth factors, etc.) have changed due to RA, and their change is a negative indicator of other body functions. Therefore, it is necessary to use some biomarkers to detect and monitor the disease before it develops, to know the extent of the relationship of these criteria to the disease, and to evaluate the functions of the body. All these are, accordingly, considered predictive criteria for the occurrence of the disease [3].

Adiponectin is a fat-derived hormone, a secretory protein produced by adipocytes and consists of 244 amino acids [4]. It is considered the most abundant in human blood among all adipokines. Adipokines are known as soluble media in the form of biologically active polypeptides (hormones, cytokines, extracellular matrix proteins (ECM), growth factors, etc.) It is produced by fat cells and preadipocytes or by immune cells filtered into the adipose tissue. It plays a major role in various physiological functions, including inflammatory ones [5].

The anti-citrulline antibody ACPA is a group of autoantibodies which are also called anti-cyclic citrullinated peptide (anti-CCP) and isotypes (IgG, IgA, IgM), which recognize non-essential amino acids citrulline – in proteins [9]. Many citrulline proteins are distinguished by ACPAs, which include Fibrinogen, Vimentin, α-enolase, Collagen type II, Keratin,

Abstract. The current study was conducted on women with rheumatoid arthritis (RA) in Basrah city, Iraq. The study aimed to evaluate the relationship between some biomarkers such as adiponectin hormone, anti-citrullinated protein antibody (ACPA), acute phase C-reactive protein (CRP) and vascular endothelial growth factor (VEGF) in the serum of female patients. In this study, 80 serum samples were collected from women and distributed as follows: 56 serum samples from women with RA and 24 serum samples from non-infected women who were considered a healthy group. The patient samples were divided into three categories depending on age, disease severity and duration. The samples were obtained from Basrah General Hospital. The results of the current study showed a significant increase in the concentration of adiponectin, ACPA, CRP and VEGF in RA patients compared to healthy subjects. In addition, there were significant differences in the concentration of these biomarkers between some of the three age groups and between the disease severity and duration. The study concluded that all the biomarkers under investigation had increased their concentrations in the serum of women suffering from RA.

Key words: Adiponectin, ACPA, CRP, VEGF, Rheumatoid Arthritis, Biomarkers
Fibronectin, Histones and others [10]. Anti-cyclic citrulline proteins (Anti-CCP) were detected in the serum of RA patients at 60-80% with a specificity of 85-99% [11]. Thus, ACPA alone has sufficient predictive power to accurately distinguish individuals at risk of developing RA from the rest of the population [12].

CRP is one of the types of blood plasma proteins, and its concentrations rise in response to inflammation, tissue damage, or when cancerous transformations occur in normal cells in the host. It is a member of the family of proteins called Pentraxins [13]. CRP is mainly produced by the liver in response to inflammation, infection, trauma, necrosis and tissue damage, malignancy, and allergic reactions. The designation of acute phase response is used to express increased concentrations of plasma proteins, including CRPs [14]. CRP is associated with various chronic inflammatory processes such as rheumatic diseases, cancerous diseases, cardiovascular diseases, chronic hepatitis, etc. [15]. In addition to the beneficial (protective) effects, CRP possesses harmful effects. This is because it contributes to atherosclerosis by activating endothelial cells to increase the expression of adhesion molecules, facilitating the adhesion of platelets and leukocytes and their aggregation, and the production of Monocyte chemotactic protein-1 (MCP-1) that attracts monocytes to the vessel wall, and the increase in the production of IL-8 that leads to the aggregation of neutrophils and their adhesion to endothelial cells, and all these roles lead to the expansion of inflammation and the development of sclerosis Arteries [16].

VEGF represents one of the angiogenic factors important for stimulating the process of generating new blood vessels, or angiogenesis, which is a complex physiological process. This process includes the division and migration of endothelial cells and the selective dissolution of the vascular basement membrane. During this process, new blood vessels are formed from pre-existing blood vessels, as in adults or the angiogenesis and growth during embryonic development [17]. The signaling protein VEGF is produced by cells that stimulate angiogenesis when hypoxia is present [18]. VEGF performs direct inflammatory activities; it exerts anti-apoptotic effects and causes the development of synovitis through hyperplasia and the formation of new blood vessels in the joints of RA patients [19]. Moreover, VEGF increases endothelial cell division, migration, survival and differentiation. It activates MMPs, attracts macrophages and granulocytes, and indirectly dilates blood vessels by releasing NO; increasing the release of these oxides enhances vascular permeability [20].

The current study aims to evaluate the concentrations of some immunological and physiological biomarkers in the serum of sick women and the relationship of these parameters to RA.

**Material and Methods**

**The patients’ group**

A total of 56 serum samples were obtained from women with RA, and the samples were divided based on age Categories into 18 serum samples for women aged 20-35 years, 19 serum samples for women aged 35-50 years, and 19 serum samples for women whose ages ranged between 50-65 years. The samples were also divided according to the severity of the disease into (severe, moderate and mild infection) and based on (Disease Activity Score-28). The disease duration was divided into two periods, the first from a month to 3 years and the second from 3 years to 20 years. The samples were collected from the joint consultants at Basrah General Hospital.

**The healthy group**

Twenty-four serum samples were obtained from healthy women after ensuring they did not have RA.

**Preparation of serum**

From each woman, 5mL of venous blood was drawn from the vein of the elbow using a clean medical syringe; then, the blood was collected in a gel tube and left for 20 minutes. Afterwards, the tube was placed in a centrifuge at a rate of 3000 rpm for 15 minutes to obtain the blood serum. The obtained serum was divided and collected in 1.5 mL Eppendorf tubes, and the samples were stored at -80ºC in deep freeze until tests were carried out.

**Estimation of the concentration of biomarkers**

The concentrations of some biomarkers (Adiponectin, ACPA, CRP, VEGF) were estimated by using the well-known immunoassay (Enzyme-Linked Immuno Assay (ELISA)) using ELISA reader, which is of American origin and the biomarker kits supplied by the American company MyBioSource, and according to the Leaflet attached to each kit.

**Statistical Analysis**

Statistical analysis of the data was carried out using the T-test and the analysis of variance (ANOVA) for the least significant difference LSD at the probability level of \( P < 0.05 \). The standard deviation was calculated using the SPSS program version 21.
Results

The results of the current study showed a significant increase at the probability level $P < 0.05$ in the concentration of adiponectin hormone in patients with RA ($68.30 ± 12.21$ ng/mL) compared to its concentration in healthy women ($51.20 ± 13.97$ ng/mL). The study also showed that significant differences were found in the concentration of this hormone among the three age categories and between moderate and mild disease severity, and the statistical analysis did not record significant differences in the concentration of (Adiponectin) according to the first and second disease duration, as shown in Table 1.

With regard to the ACPA antibodies, the results showed that a significant increase in the concentration of the ACPA antibodies was found in patients ($207.94 ± 69.06$ ng/mL) compared to its concentration in healthy women ($17.95 ± 7.06$ ng/mL). The results also showed significant differences in the concentration of this biomarker according to the three age categories, the disease severity and duration, as shown in Table 2.

The results of the current study showed a significant increase in the concentration of acute phase protein CRP in rheumatic patients ($1186.89 ± 318.16$ pg/mL) compared to its concentration in healthy control ($867.58 ± 271.03$ pg/mL). The current study also found significant differences in the concentration of CRP among the three age categories and the severity of the disease. However, the study did not report significant differences in the concentration of this protein in the two duration of illness, as shown in Table 3.

The results of the current study showed a significant increase in the concentration of VEGF in RA patients ($207.58 ± 44.45$ pg/mL) compared to its concentration in healthy control ($17.50 ± 6.40$ pg/mL). The statistical analysis showed significant differences in the concentration of this biomarker among the categories according to age, the severity of the disease and the two duration of illness, as shown in Table 4.

Table 1. Serum concentration of Adiponectin hormone

| Variables       | No.  | Mean ± SD          | P value |
|-----------------|------|--------------------|---------|
| Participants    |      |                    |         |
| Rheumatoid arthritis | 56   | 68.30 ± 12.21 ng/mL* | 0.0001  |
| Healthy control | 24   | 51.20 ± 13.97 ng/mL |         |
| Age (years)     |      |                    |         |
| 20-35           | 18   | 59.27 ± 6.36 a     | 0.0001  |
| 35-50           | 19   | 71.89 ± 9.78 b     |         |
| 50-65           | 19   | 73.26 ± 10.19 b    |         |
| Severity        |      |                    |         |
| Severe          | 16   | 67.37 ± 10.99      | 0.036   |
| Moderate        | 32   | 70.81 ± 10.64 a    |         |
| Mild            | 8    | 60.12 ± 6.64 b     |         |
| Disease duration|      |                    |         |
| 1 Month – 3 years | 26   | 69.38 ± 14.46     | 0.581   |
| 3 years – 20 years | 30   | 67.36 ± 12.74     |         |

* Significant difference at the probability level of $P < 0.05$ in the group of patients compared to the group of healthy subjects. The different letters (a, b) indicate that there were significant differences between the Categories at ($P < 0.05$)

Table 2. Concentration of ACPA

| Variables       | No.  | Mean ± SD          | P value |
|-----------------|------|--------------------|---------|
| Participants    |      |                    |         |
| Rheumatoid arthritis | 56   | 207.94 ± 69.06 ng/mL* | 0.0001  |
| Healthy people  | 24   | 17.95 ± 7.06 ng/mL |         |
| Age (years)     |      |                    |         |
| 20-35           | 18   | 184.61 ± 43.92 a   | 0.014   |
| 35-50           | 19   | 215.63 ± 33.33 b   |         |
| 50-65           | 19   | 222.36 ± 42.81 b   |         |
| Severity        |      |                    |         |
| Severe          | 16   | 284.06 ± 41.61 a   | 0.0001  |
| Moderate        | 32   | 243.69 ± 37.67 b   |         |
| Mild            | 8    | 189.37 ± 44.07 c   |         |
| Disease duration|      |                    |         |
| 1 Month – 3 years | 26   | 138.80 ± 20.97 *   | 0.0001  |
| 3 years – 20 years | 30   | 267.86 ± 27.66 *   |         |

*Significant difference at the probability level of $P < 0.05$ in the group of patients compared to the group of healthy. The different letters (a, b, c) indicate that there were significant differences between the Categories at ($P < 0.05$)
The adipokines, including adiponectin, are important inflammatory mediators that play a critical role in autoimmune diseases. Their importance results from their many biological properties, including their interaction with the immune system. Adiponectin exerts a pro-inflammatory activity in the joints and stimulates their erosion and breakdown mechanisms despite its strong anti-inflammatory effects and improving insulin sensitivity [21]. The results of the current study showed a significant increase in the concentration of adiponectin in patients with RA (68.30 ± 12.21 ng/mL) compared to healthy women (51.20 ± 13.97 ng/mL), and our results agreed with the results of other studies [22, 23]. The reason for the high concentration of adiponectin may be attributed to the roles that adiponectin plays in regulating the inflammatory response through inhibiting the production of adhesion molecules, suppressing macrophage function, and inhibiting NF-kB signaling [24]. Or the reason for the increase may be explained by looking at the anti-inflammatory regulatory function of adiponectin, which counteracts the pro-inflammatory effects of inflammatory cytokines, inhibits them and stimulates the release of anti-inflammatory factors [25].

Regarding the effect of age on the concentration of adiponectin, the results of our study showed significant differences in the concentration of this hormone among the three age categories. These results agree with the study by Bucci et al. [26]. The reason for the increase may be due to the increase in the production of this hormone from adipose tissue and other tissues such as the liver and skin at aging. With regard to the effect of disease severity on adiponectin concentration in patients’ serum, si-
nificant differences were obtained between moderate and mild disease severity only. Adiponectin has been identified as a factor associated with disease severity and joint destruction in several previous studies [27, 28, 29]. The study by Liu et al. [30] reported that the concentration of adiponectin increases significantly in the serum of patients with active RA compared to healthy patients or patients with inactive RA, and the researchers noticed a positive association of adiponectin with the disease severity scale, ESR and RF. As for the disease duration and its effect on the concentration of this biomarker, we did not notice any significant differences between the two courses of the disease.

The results of the current study showed a significant increase in the concentration of ACPA antibody in the serum of patients (207.94 ± 69.06 ng/mL) compared to healthy women (17.95 ± 7.06 ng/mL), and these results were consistent with the findings of other studies [31, 32]. The reason for the high concentration of ACPA may be due to the formation of immune complexes as a result of the association of the types of ACPAs produced by B cells with citrullinated proteins in the synovial membrane of the joint, which leads to the activation of macrophages to produce many cytokines that initiate inflammation. Moreover, the production of ACPAs promotes the development of osteoclasts and, thus, joint destruction by causing erosion of bone and cartilage [33]. ACPA affects immune cells and enhances the production of more inflammatory and oxidative indices in monocytes, lymphocytes, and neutrophils. It was found that it activates platelets, which may contribute to atherosclerosis through the accumulation of pro-inflammatory mediators, endothelial tissue damage, and increased vascular permeability [34].

The results of the current study also showed significant differences in the concentration of ACPA depending on age. Our results agreed with the results of previous studies [35, 36]. The reason why the concentration of ACPA remains elevated with age may be due to the fact that it may appear several years before the onset of disease symptoms and before the onset of inflammation, and then it increases with the onset of disease symptoms and joint destruction [37].

The results also showed significant differences in the concentration of ACPA in all types of disease severity (severe, moderate and mild), and the highest concentration was recorded in severe disease. The results of our study agreed with the results of the study by Roos Ljungberg et al. [38]. This study revealed an increase in the concentration of ACPA-IgA antibody by 12% in saliva and by 45% in the serum of RA patients, and this increase was associated with a higher activity of the disease. The reason for this can be attributed to the fact that the production of citrulline proteins increases with the increase in the severity of the disease in the inflamed tissues of patients, which leads to an increase in autoantibodies, especially ACPA [39]. As for the effect of the disease duration on the concentration of ACPA, the results showed a significant increase in the concentration of this biomarker between the two periods of illness, and this was consistent with the results of the study by Kastbom et al. In addition, they found significant differences in the concentrations of ACPAs, which were associated with the long duration of the disease [31]. This may be due to the effect of the concentration of ACPA on anti-inflammatory treatments.

The results of the current study showed a significant increase in the concentration of acute phase protein CRP in rheumatic patients (1186.89 ± 318.16 pg/mL) compared to its concentration in healthy women (867.58 ± 271.03 pg/mL). This is because the acute phase proteins show a marked increase under different conditions such as bacterial infections, connective tissue disorders, abscesses, necrosis, tumors, etc. Therefore CRP is an important diagnostic tool for detecting inflammation [13]. The results of our study are in agreement with the findings of other studies [40, 41, 42]. The high concentration of this protein in the serum of patients may be due to the sex difference, as some studies indicated that the concentration of CRP was higher in females than in males [43, 44]. The reason for this may be due to genetic differences, hormonal factors, or the prevalence of obesity in women, which stimulate the production of more (IL-6), which in turn works to regulate the secretion of acute phase proteins [45].

Regarding the effect of age on acute phase protein concentration in patients, we found significant differences in CRP concentration among the age groups studied. These results agree with the results of previous studies that showed a significant association between getting old and increasing CRP concentration [45, 46]. The reasons for the increase in protein concentration with age may be due to differences in lifestyle and weight gain in women, as the increase in body mass stimulates the production of IL-6, which leads to an increased CRP production, as well as changes in hormonal factors after menopause or the occurrence of some immunity changes and metabolism changes [47]. As for the effect of disease severity on increasing CRP concentration in patients, the results showed significant differences in protein concentration between severe, moderate
and mild infections. Several studies confirmed the close relationship between an increase in CRP concentration and an increase in disease severity and the contribution of the protein to the pathogenesis of rheumatic disease [48, 49]. The reason for the rise in the concentration of CRP may be related to the activity or severity of the disease as a result of the large role that this protein plays in stimulating osteoclast cells and the resulting increase in joint destruction in severe disease [50].

The results of the current study showed a significant increase in the concentration of VEGF in patients with RA (207.58 ± 44.45 pg/mL) compared to its concentration in healthy women (17.50 ± 6.40 pg/mL), as many studies [51, 52, 53] reported similar results to what we found. The reason for the high concentration of this biomarker in the serum of patients may be attributed to the fact that rheumatoid disease is an inflammatory disease that causes the occurrence of tissue hyperplasia and the formation of fibrous vascular tissue or the so-called Pannus, which leads to a lack of oxygen and in turn stimulates the production of more vascular growth factors that work to generate blood vessels. This process promotes the delivery of inflammatory cells to the site of damage. Thus, inflammation-initiating cytokines are produced and released from inflammatory cells; therefore, VEGF acts as a functional bridge between angiogenesis and inflammation [54, 55].

As for the effect of age on the concentration of VEGF, the results showed significant differences in concentration according to the different age categories. These results agreed with the findings of Smets et al., who reported an increase in the concentration of VEGF in the serum with the advancing age of patients [56]. This increase indicated an exacerbation of the inflammatory condition in patients and was associated with an increase in acute phase reactants and the number of platelets. With regard to the effect of disease severity on the concentration of VEGF, the results showed significant differences in the concentration of this factor between severe infection with both moderate and mild infection, and many studies showed a higher concentration of vascular factors as the severity of the disease increased [57, 58, 59]. It was also observed that the concentration of VEGF in the serum increases with the increase in disease activity, the rise in CRP, and the number of swollen joints; therefore, the researchers suggested that the level of this factor expresses the activity and severity of the disease [51]. Thus, it is normal to increase the concentration of vascular factors when the severity and activity of the disease increase due to the increased production of inflammatory cytokines, which stimulate cells to produce more VEGF.

As for the effect of the disease duration on the concentration of VEGF, the results showed significant differences between the periods, and the results of our study agreed with the results of previous studies [60, 61]. The reason for the rise in vascular growth factors in the late stages of the disease (the second time period) may be attributed to the poor therapeutic control of the disease.

Conclusions

The current study concluded that all the biomarkers under investigation had increased their concentrations in the serum of women suffering from RA, which indicates the association of these biomarkers with the inflammatory reactions that occur in patients with RA. These high concentrations of these parameters can help predict the therapeutic effects and can be adopted as biomarkers for early detection of RA.

References

1. Bathon J, Tehlirian C. RA clinical and laboratory manifestations. In: Klippel JH, Stone JH, Crofford LJ, et al., eds. Primer on the Rheumatic Diseases. 13th ed. New York, NY: Springer; 2008,114-121.
2. Smolen JS, Landewé R, Bijlsma J et al. EULAR recommendations for the management of RA with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the rheumatic diseases, 2017,76(6), 960-977. doi:10.1136/annrheumdis-2016-210715.
3. Aletaha D, Neogi T, Silman AJ et al. 2010 RA classification criteria: an American College of Rheumatology/European League Against RA collaborative initiative. Arthritis & RA, 2010,62(9), 2569-2581. doi:10.1016/j.artd.27584.
4. Wang ZV, Scherer PE. Adiponectin, the past two decades. Journal of molecular cell biology, 2016,8(2), 93-100. doi:10.1093/jmcb/mjw011.
5. Weschenfelder C, Schaan de Quadros A, Lorenzon dos Santos J et al. Adipokines and adipose tissue-related metabolites, nuts and cardiovascular disease. Metabolites, 2020,10(1), 2032. doi:10.3390/metabo10010032.
6. Berendoncks AMV, Stensvold D, Garnier A et al. Disturbed adiponectin – AMPK system in skeletal muscle of patients with metabolic syndrome. European journal of preventive cardiology, 2015,22(2), 203-205. doi:10.1177/204748331580034.
7. Parker-Duffen JL, Nakamura K, Silver M et al. T-cadherin is essential for adiponectin-mediated revascularization. Journal of Biological Chemistry, 2013,288(34), 24886-24897. doi:10.1074/jbc.M113.454835.
8. Fantuzzi G. Adipose tissue, adipokines, and inflammation. Journal of Allergy and clinical immunology, 2005,115(5), 911-919. doi:10.1016/j.jaci.2005.02.023.
9. Kurowsk, W, Kuca-Warnawin EH, Radzikowska A, Maśliński W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of RA. Central-European journal of immunology, 2017,42(4), 390-398. doi:10.5114/ceji.2017.72807.
10. Lee CY, Wang D, Wilhelm M et al. Mining the human tissue proteome for protein citrullination. Molecular & Cellular Proteomics, 2018,17(7), 1378-1391. doi.org/10.1074/mcp.RA118.000696.

11. Aggarwal R, Liao K, Nair R et al. Anti-citrullinated peptide antibody assays and their role in the diagnosis of RA. Arthritis and RA, 2009,61(11), 1472-1483. DOI: 10.1002/art.24827.

12. Hensvold AH, Frisell T, Magnusson P et al. How well do ACPP discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins. Annals of the rheumatic diseases, 2017,76(1), 119-125.

13. Pepys MB, Hirschfield GM. C-reactive protein: a critical protein. The Journal of clinical investigation, 2003,111(12), 1805-1812. doi.org/10.1172/JCI18921.

14. Bray C, Bell LN, Liang H et al. Erythrosine Sedimentation Rate and C-Reactive Protein measurements and their relevance in clinical medicine. Wisconsin Medical Journal (WJM). 2016,115 (6): 317-321.

15. Devaraj S, Valleaggi S, Siegel D, Jialal I. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Current atherosclerosis reports, 2010,12(2), 110-118. DOI: 10.1007/s11883-010-0098-3.

16. McFadyen JD, Kiefer J, Braig D et al. Dissociation of C-reactive protein localizes and amplifies inflammation: evidence for a direct biological role of C-reactive protein and its conformational changes. Frontiers in immunology, 2018,9, 1351. doi.org/10.3389/fimmu.2018.01351.

17. Birbrair A, Zhang T, Wang Z et al. Pericytes at the intersection between tissue regeneration and pathology. Clinical science, 2015,128(2), 81-93. doi.org/10.1042/CS20140278.

18. Holmes K, Roberts OL, Thomas A M, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cellular & Molecular Medicine, 2013,17(3), 386-397. doi.org/10.1111/jcmm.2007.05.013.

19. Selvaraj SK, Giri RK, Perelman N et al. Mechanism of monocyte activation and expression of proinflammatory cytokines by placenta growth factor. Blood, 2003,102 (4): 1515-1524. doi.org/10.1182/blood-2002-11-3423.

20. Tang X, Yang Y, Yuan H et al. Novel transcriptional regulation of VEGF in inflammatory processes. Journal of cellular and molecular medicine, 2013,17(3), 386-397. doi.org/10.1111/jcmm.12020.

21. Peng YJ, Shen TL, Chen YS et al. Adiponectin and adiponectin receptor 1 overexpression enhance inflammatory bowel disease. Journal of biomedical science, 2018,25(1), 1-13. doi.org/10.1186/s12929-018-0419-3.

22. Lee YH, Bae SC. Circulating adiponectin and visfatin levels in RA and their correlation with disease activity: A meta-analysis. International journal of rheumatic diseases, 2018,21(3), 664-672. doi.org/10.1016/j.ijrheum.2017.10.009.

23. Zhang Y, Peltonen M, Andersson-Assarson JC et al. Elevated adiponectin predicts the development of RA in subjects with obesity. Scandinavian Journal of Rheumatology, 2020,49(6), 452-460. doi.org/10.1080/03009742.2020.1753808.

24. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones, 2012,11(1), 8-20. doi.org/10.1007/s10749-013-9047-0.

25. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clinica chimica acta, 2007,380(1-2), 24-30. doi.org/10.1016/j.cca.2007.01.026.

26. Buccigrossi A, Baffi C et al. Circulating levels of adipokines and IGF-1 are associated with skeletal muscle strength of young and old healthy subjects. Biogerontology, 2013,14(3), 261-272. doi.org/10.1007/s10522-013-9428-5.

27. Rho YH, Solus J, Sokka T et al. Adipocytokines are associated with radiographic joint damage in RA. Arthritis & RA: Official Journal of the American College of Rheumatology, 2009,60(7), 1906-1914. doi.org/10.1016/j.art.24626.

28. Giles JT, Allison M, Bingham III CO et al. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in RA. Arthritis Care & Research: Official Journal of the American College of Rheumatology, 2009,61(9), 1248-1256. doi.org/10.1002/art.24789.

29. Klein-Wieringa IR, van der Linden MP, Knevel R et al. Baseline serum adipokine levels predict radiographic progression in early RA. Arthritis & RA, 2011,63(9), 2567-2574. doi.org/10.1002/art.30449.

30. Liu T, Tan W, Zhang M. Change and clinical significance of adiponectin in patients with RA. Jiangsu Medical Journal, 2010,36, 1744-1746.

31. Kastbom A, Roos Ljungberg K, Ziegelasch M et al. Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early RA. Clinical & Experimental Immunology, 2018, 194(3), 391-399. doi.org/10.1111/cei.13206.

32. Kelmenson LB, Wagner BD, McNair BK et al. Timing of elevations of autoantibody isotypes prior to diagnosis of RA. Arthritis & Rheumatology, 2020,72(2), 251-261. doi.org/10.1002/art.41091.

33. Krishnamurthy A, Joshua V, Hensvold AH et al. Identification of a novel chemokine-dependent molecular mechanism underlying RA-associated autoantibody-mediated bone loss. Annals of the rheumatic diseases, 2016,75(4): 721-729. doi.org/10.1136/annrheumdis-2015-208093.

34. Barbarroja N, Pérez-Sanchez C, Ruiz-Limon P et al. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in RA. Arteriosclerosis, thrombosis, and vascular biology, 2014,34(12), 2706-2716. doi.org/10.1161/ATVBAHA.114.304475.

35. Vadasz Z, Haj T, Kessel A, Toubi E. Age-related immunomunity. BMC Medicine, 201311(1), 1-4. doi.org/10.1186/1741-7015-11-94.

36. Van Zanten A, Arends S, Roozendaal C et al. Presence of anti-citrullinated protein antibodies in a large population-based cohort from the Netherlands. Annals of the rheumatic diseases, 2017,76(7), 1184-1190. doi.org/10.1136/annrheumdis-2016-209991.

37. Kokkonen H, Mullazehi M, Berglin E et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide preceed the development of RA. Arthritis research & therapy, 2011,13(1), 1-10. doi.org/10.1186/ar3237.

38. Roos Ljungberg KR, Börjesson E, Martinsson K et al. Presence of salivary IgA anti-citrullinated protein antibodies associated with higher disease activity in patients with RA. Arthritis research & therapy, 2020,22(1), 1-10. doi.org/10.1186/s13075-020-02363-0.

39. Engström M, Eriksson K, Lee L et al. Increased citrullination and expression of peptidylarginine deiminases independently of P. gingivalis and A. actinomyctecomatis in gingival tissue of patients with periodontitis. Journal of translational medicine, 2018,16(1), 1-14. doi.org/10.1186/s12967-018-1588-2.

40. Graf J, Scherer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with RA. PLoS One, 2009,4(7), e6242. doi.org/10.1371/journal.pone.0006242.
41. Shrivastava AK, Singh HV, Raizada A et al. Inflammatory markers in patients with RA. Allergologia et Immunopathologia, 2015,43(1), 81-87. doi.org/10.1016/j.aller.2013.11.003.

42. Bay-Jensen AC, Platt A, Jenkins MA et al. Tissue metabolism of type I collagen, C1M, and CRP predict structural progression of RA. BMC rheumatology, 2019,3(1), 1-10. doi.org/10.1186/s41927-019-0052-0.

43. Pieroni L, Bastard JP, Piton A et al. Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. Diabetes & metabolism, 2003,29(2),133-138. doi.org/10.1016/S1262-3636(07)70019-8.

44. Lakoski SG, Cushman M, Criqui M et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. American Heart Journal, 2006,152(3), 593-598. doi.org/10.1016/j.ahj.2006.02.015.

45. Kawamoto R, Kusunoki T, Abe M et al. An association between body mass index and high-sensitivity C-reactive protein concentrations is influenced by age in community-dwelling persons. Annals of clinical biochemistry, 2013,50(5), 457-464. DOI:10.1177/0004563212473445.

46. Siemons L, Ten Klooster PM, Vonkeman HE et al. How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early RA. BMC Musculoskeletal Disorders, 2014,15(368), 1-7. doi.org/10.1186/1471-2474-15-368.

47. Kao TW, Lu IS, Liao KC et al. Associations between body mass index and serum levels of C-reactive protein. South African Medical Journal, 2009, 99(5),326-330.

48. Dessein PH, Joffe BI, Stanwix AE. High sensitivity C-reactive protein as a disease activity marker in RA. The Journal of rheumatology, 2004,31(6), 1095-1097.

49. Cylwik B, Chrostek L, Gindzienska-Sieskiewicz E et al. Relationship between serum acute-phase proteins and high disease activity in patients with RA. Advances in Medical Sciences, 2010,55(1), 80-85. doi.org/10.2478/v10039-010-0006-7.

50. Kim K-W, Kim B-M, Moon H-W et al. Role of C-reactive protein in osteoclastogenesis in RA. Arthritis Research & Therapy, 2015,17(1),1-12. doi.org/11.1186/s13075-015-0563-z.

51. Lee SS, Joo YS, Kim WU et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with RA. Clinical and Experimental Rheumatology, 2001,19(3), 321-324.

52. Koch AE. Angiogenesis as a target in RA. Annals of the rheumatic diseases, 2003,62(suppl 2), 60-67. doi.org/10.1136/ard.62.suppl_2.ii60.

53. Lee YH, Bae SC. Correlation between circulating VEGF levels and disease activity in RA: a meta analysis. Zeitschrift für Rheumatologie, 2016,77(3),240-248. doi.org/10.1007/s00393-016-0229-9.

54. Azizi G, Boghozian R, Mirshafiey A. The potential role of angiogenic factors in RA. International journal of rheumatic diseases, 2014,17(4), 369-383. doi:10.1111/1756-185x.12280.

55. Kim HR, Kim KW, Kim BM et al. The effect of vascular endothelial growth factor on osteoclastogenesis in RA. PLoS One, 2015,10(4), e0124909. doi.org/10.1371/journal.pone.0124909.

56. Smets P, Devauchelle-Pensec V, Rouzaire PO et al. Vascular endothelial growth factor levels and rheumatic diseases of the elderly. Arthritis research and therapy, 2016,18(1), 1-6. DOI 10.1186/s13075-016-1184-x.

57. Taylor PC. Serum vascular markers and vascular imaging in assessment of RA disease activity and response to therapy. Rheumatology, 2005,44(6), 721-728. doi.org/10.1093/rheumatology/keh524.

58. Vordenbäumen S, Sewerin P, Lögters T et al. Inflammation and vascularisation markers of arthroscopically-guided finger joint synovial biopsies reflect global disease activity in RA. Clinical and experimental rheumatology, 2014,32(1), 117-120.

59. Kim JW, Kong JS, Lee S et al. Angiogenic cytokines can reflect the synovitis severity and treatment response to biologics in RA. Experimental & molecular medicine, 2020,52(5), 843-853. doi.org/10.1038/s12276-020-0443-8.

60. Pinheiro GRC, Andrade CAF, Gayer CR et al. Serum vascular endothelial growth factor in late RA. Clinical and experimental rheumatology, 2001,19(6), 721-723. doi:10.1136/annrheumdis-2015-208980.

61. Ozgonenel L, Cetin E, Tutun S et al. The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with RA. Clinical rheumatology, 2010,29(5), 473-477. doi.org/10.1007/s10067-009-1343-4.

Submitted: 14.06.2022

Correspondence address: Muneera M. Adlan Basrah, Iraq Medicalresearch55@yahoo.com 61001 +964 780 146 6023